IPO Issue Details
Issue Price / Price Band₹85 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size1,600 Shares per Lot
Total Issue Size33,08,800 shares (aggregating up to ₹28.12 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital
Exchange / PlatformNSE SME
IPO TypeSME
Subscription OpenMon, 01 Dec 2025
Subscription CloseWed, 03 Dec 2025
Anchor AllotmentSun, 30 Nov 2025
Basis of AllotmentThu, 04 Dec 2025
Initiation of RefundsFri, 05 Dec 2025
Credit of Shares to DematFri, 05 Dec 2025
Listing DateMon, 08 Dec 2025
UPI Mandate Deadline2025-12-03
Application & Investment Details
Retail — Min (2 Lots)₹2,72,000 — 3,200 shares
Retail — Max (13 Lots)₹1,768,000 (13 Lots)
HNI — Min (3 Lots)₹4,08,000 — 4,800 shares
EPS (Pre-IPO)₹5.86
EPS (Post-IPO)₹6.50
P/E Ratio (Pre-IPO)14.51x
P/E Ratio (Post-IPO)13.08x
Net Offer to Public31,42,400 shares (aggregating up to ₹26.71 Cr)
Reserved for Market Maker1,66,400 shares (aggregating up to ₹1.41 Cr)
Pre-IPO Promoter Holding92,63,173 shares
Post-IPO Promoter Holding1,25,71,973 shares
About Invicta Diagnostic Ltd
Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions. The company provides pathology and radiology testing, including imaging, radiology, and teleradiology, under the brand 'PC Diagnostics' through 7 diagnostic centres and a central laboratory across Mumbai, Maharashtra.Invicta Diagnostics Limited (trading as PC Diagnostics) is a Mumbai-based diagnostic services company specialising in integrated pathology and radiology solutions. The company follows a hub‑and‑spoke model across the Mumbai Metropolitan Region, featuring:A flagship hub in Thane West offering full-spectrum pathology and advanced radiology (PET CT, MRI)Three additional hubs (Bhayandar, Byculla, Marol) providing specialised diagnostic servicesThree spokes in Lower Parel, Sewri, and Kalwa focused on basic imaging (X-ray, ultrasound) and sample collection.The company offers around 60 routine and 487 specialised pathology tests, plus about 96 basic and 130 advanced radiology tests.Invicta Diagnostics provides a comprehensive suite of diagnostic services, which includes:Routine Tests: Includes CBC, lipid profiles, liver function tests (LFT), kidney function tests (KFT), and thyroid panelsSpecialised Tests: Covers molecular diagnostics, immunoassays, infectious disease markers (e.g., dengue, COVID-19), cancer markers, and genetic panelsSample Collection Network: Invicta uses phlebotomists and collection partners to reach patients at home or through its spoke centres.As of October 31, 2025, the company employed 157 permanent employees.Competitive Strength:Expanding presence in the Mumbai Metropolitan Region (“MMR”), specifically in the radiology sector;A diagnostics provider that offers a one-stop solution at an affordable price.Technical capability and technology with IT infrastructure;Dedicated management team with significant industry experience; andImplementation of the Hub and Spoke Model.
Objects of the Issue
Invicta Diagnostic Ltd proposes to utilise the net proceeds from the Issue for the following objects:
1
Funding capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra; and
21.11
2
General Corporate purposes
4.07
Shareholding & Lock-in
Pre-IPO Promoter Holding
92,63,173 shares
Post-IPO Promoter Holding
1,25,71,973 shares